From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

Interview With Justina Kiernan, PA-C: Advancing Myeloma Care–New Strategies for Relapsed Disease Management

Interview With Justina Kiernan, PA-C: Discussing New Frontiers in Multiple Myeloma Immunotherapy

Interview with Sara Scott, PharmD, BCOP: Outpatient Protocols and Patient Management of Bispecific Antibodies

Interview with Sara Scott, PharmD, BCOP: Highlights from the 2025 International Myeloma Society Annual Meeting

Emerging and Re-emerging Therapeutic Strategies in Multiple Myeloma

Innovations in Multiple Myeloma Treatment

Interview with Ann McNeill, RN, MSN, APN: Bispecific T-Cell Engager Therapy Considerations and Collaboration

Interview with Ann McNeill, RN, MSN, APN: Bispecific T-Cell Engager Therapy Administration and Management

Interview with Danielle Roberts, PA-C: Sequencing of Bispecific Antibodies and CAR T-Cell Therapies

Interview with Danielle Roberts, PA-C: Onboarding APPs New to Multiple Myeloma Practice

Interview with Dennis Verducci, MSN, RN, NP-BC, OCN: Evolving Technology and Monitoring of Disease

Interview with Dennis Verducci, MSN, RN, NP-BC, OCN: Real-World Treatment and Transplant Strategies

The New Role of MRD Testing in Trials and Treatments

New Trial Data and the Ever-Changing Treatment Landscape

Interview with Sara Scott, PharmD, BCOP: Evolving Treatment Methods

Interview with Sara Scott, PharmD, BCOP: Role of the Clinical Pharmacist and the Multi-team Approach

Interview with Mary Steinbach, DNP, APRN: Clinical Trials and the Role of the AP

Interview with Mary Steinbach, DNP, APRN: Bispecifics vs CAR T-Cell Therapy in Multiple Myeloma Treatment

Interview with Amy Pierre, MSN, ANP-BC: Treatment and Care Inequities in Black Patients with Multiple Myeloma

Interview with Amy Pierre, MSN, ANP-BC: Choosing the Best Treatment Option for Your Patient

Bispecific Antibody Management in Relapsed Multiple Myeloma

Functional High-Risk Multiple Myeloma

Linvoseltamab in Relapsed/Refractory Multiple Myeloma